Due to its additional role in inflammation that is implicated in wet AMD, ANG2 has become a potential therapeutic target in wet AMD beyond anti-VEGF therapies (Gahn and Khanani, 2018). This evidence concerns the gene ANGPT2 and wet macular degeneration.